Evidence map›Paper›PMID 24263157›Full record

ArticleCancer gene therapy2013

Heat-shock protein 90 inhibitors synergistically enhance melanoma differentiation-associated gene-7-mediated cell killing of human pancreatic carcinoma.

Z Zhang, K Kawamura, Y Jiang, M Shingyoji, G Ma, Q Li, J Hu, Y Qi, H Liu, F Zhang and 5 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Interleukin-24: A Multidimensional Therapeutic for Treatment of Human Diseases.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Z Zhang1] Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chuo-ku, Chiba, Japan [2] Department of Gynecology and Obstetrics, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
K KawamuraDivision of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chuo-ku, Chiba, Japan.
Y Jiang1] Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chuo-ku, Chiba, Japan [2] Department of Molecular Biology and Oncology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan.
M ShingyojiDepartment of Thoracic Diseases, Chiba Cancer Center, Chuo-ku, Chiba, Japan.
G Ma1] Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chuo-ku, Chiba, Japan [2] Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Q Li1] Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chuo-ku, Chiba, Japan [2] Department of Molecular Biology and Oncology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan [3] Department of Immunology, Basic Medical College, Hebei Medical University, Shijiazhuang, China [4] Cell Therapy Center, The First Hospital of Hebei Medical University, Shijiazhuang, China.
J HuDepartment of Immunology, Basic Medical College, Hebei Medical University, Shijiazhuang, China.
Y QiDepartment of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
H LiuDivision of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chuo-ku, Chiba, Japan.
F ZhangDepartment of General Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
S KangDepartment of Gynecology and Obstetrics, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
B ShanResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
S WangDepartment of Endoscopy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
S ChadaSVP Translational Medicine, Intrexon Corporation, Germantown, MD, USA.
M Tagawa1] Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chuo-ku, Chiba, Japan [2] Department of Molecular Biology and Oncology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan.
Chiba Cancer Center · JPHebei Medical University · CNChiba University · JPExxonMobil (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is one of the intractable diseases and an effective therapeutic strategy is required to improve the prognosis. We examined possible antitumor effects of adenoviruses expressing melanoma differentiation-associated gene-7/interleukin-24 (Ad-mda-7) and a heat-shock protein 90 (Hsp90) inhibitor to human pancreatic carcinoma cells. Ad-mda-7 and an Hsp90 inhibitor, geldanamycin (GA), produced cytotoxic effects, and a combinatory use of Ad-mda-7 and GA further achieved synergistic effects. Administration of N-acetyl-L-cysteine, an inhibitor of reactive oxygen species, eliminated Ad-mda-7- and GA-mediated cytotoxicity. Ad-mda-7 augmented phosphorylated AKT levels but GA did not influence the phosphorylation. GA-treated cells showed cleavage of poly-(ADP-ribose) polymerase but not caspase-3, and upregulated Hsp70 and LC3A/B II levels, whereas Ad-mda-7-treated cells did not. GA treatments augmented ubiquitination and markedly increased melanoma differentiation-associated gene-7 (MDA-7) expression levels. These findings suggest that Ad-mda-7-mediated cytotoxicity is dependent on reactive oxygen species but independent of apoptosis or autophagy, and that GA-mediated cytotoxicity was linked with caspase-independent apoptosis and/or autophagy. A mechanism underlying the combinatory effects of Ad-mda-7 and GA remained complex and the synergism is attributable to multiple factors including increased MDA-7 protein stability by GA.

Indexed as

AdenoviridaeBenzoquinonesCell CycleCell Line, TumorCytotoxicity, ImmunologicDrug SynergismGene ExpressionGenetic VectorsHSP90 Heat-Shock ProteinsHumansInterleukin-24InterleukinsLactams, MacrocyclicPancreatic NeoplasmsTransduction, GeneticBenzoquinonesgeldanamycinHSP90 Heat-Shock ProteinsInterleukin-24InterleukinsLactams, Macrocyclic

Identifiers

PMID24263157
OpenAlexW2086506656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.